Published August 2026, Li-Fraumeni Syndrome: Current Perspectives, is a comprehensive review on previously published work regarding molecular pathogenesis, international surveillance strategies, clinical management, and other pediatric considerations to include psychosocial implications, relative to LFS.
Genetic testing is not always a one and done process: the classification of a variant may change over time, technologies improve and better testing may become available; and guidelines and recommendations for testing and management change as we learn new information. This case in “Genetic Testing Challenges in Oncology" highlights some of these issues. The
The American Association of Cancer Research (AACR) has published a useful article on the financial impact of young adults who have been diagnosed with cancer in their Cancer Today magazine. The article provides financial resources (to include Dollar For, etc.) and practical tips for navigating the burden of medical costs (such as requesting payment plans with
Researchers continue to study the psycho-social impact of Li-Fraumeni syndrome on young adults and their concerns about LFS, determining that effectively managing the challenges requires interdisciplinary care teams, including mental health providers, genetic counselors, and physicians. Read more here. (2025)
US-based researchers assessed the performance of (non-contrast) annual whole-body MRI as part of a multimodality screening for individuals with Li-Fraumeni syndrome for early cancer detection. These researchers concluded that, in conjunction with other methods endorsed by LFS guidelines, annual wbMRI substantially contributes to the detection of localized, asymptomatic cancers across the spectrum of LFS. The
New prospective data from a German study indicate that annual whole-body MRI for LFS surveillance could be shortened and may not require contrast agent while still detecting new cancers. Larger studies are needed before this becomes standard practice to ensure reliable detection across the entire, diverse LFS tumor spectrum. The goal is a patient-friendly,
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association for Cancer Research (AACR), as published in Clinical Cancer Research on May 15, 2025. These evidence-based updates offer important changes to surveillance protocols aimed at improving early cancer detection and care for individuals living with LFS. The
Li-Fraumeni syndrome (LFS) researchers in Brazil studied factors in determining quality of life issues for women living with LFS who consider risk-reducing mastectomies – one of the few available options to reduce cancer risks in women beyond surveillance. When reviewing this study, keep in mind that the majority of participants in the study carry the
Published March 2025 by American Association for Cancer Research (AACR) is the updated version of the “Toronto Protocol,” the widely recognized screening recommendations for Li-Fraumeni syndrome patients, worldwide. Lead by Dr. David Malkin (LFSA Medical & Scientific Board Member and Co-chair of LFSA – Canada), this new perspective provides an up-to-date clinical overview of
UK researchers conducted a retrospective case-series study of four children diagnosed with solid cancers at age 16 or younger, aiming to assess the time to and survival following a second cancer diagnosis. In those who received radiotherapy for the initial cancer, the median time to a second primary cancer diagnosis was 13.3 years, with a
P.O. Box 6458
Holliston, MA 01746, USA
Phone: 1-833-4MYLFSA (1-833-469-5372)
Email: info@lfsassociation.org
© Copyright 2026 | Li-Fraumeni Syndrome Association | All Rights Reserved | Terms & Conditions | Privacy Policy | Accessibility Statement
